Last reviewed · How we verify
CB-03-10
At a glance
| Generic name | CB-03-10 |
|---|---|
| Sponsor | Cosmo Technologies Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CB-03-10 CI brief — competitive landscape report
- CB-03-10 updates RSS · CI watch RSS
- Cosmo Technologies Ltd portfolio CI